Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive Properties.
Krug AW, Visser SAG, Tsai K, Kandala B, Fancourt C, Thornton B, Morrow L, Kaarsholm NC, Bernstein HS, Stoch SA, Crutchlow M, Kelley DE, Iwamoto M. Krug AW, et al. Among authors: morrow l. Clin Pharmacol Ther. 2019 Feb;105(2):417-425. doi: 10.1002/cpt.1215. Epub 2018 Sep 30. Clin Pharmacol Ther. 2019. PMID: 30125349 Clinical Trial.
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Crutchlow MF, Palcza JS, Mostoller KM, Mahon CD, Barbour AM, Marcos MC, Xu Y, Watkins E, Morrow L, Hompesch M. Crutchlow MF, et al. Among authors: morrow l. Diabetes Obes Metab. 2018 Feb;20(2):400-408. doi: 10.1111/dom.13084. Epub 2017 Sep 26. Diabetes Obes Metab. 2018. PMID: 28817223 Free PMC article. Clinical Trial.
Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection.
Krug AW, Vaddady P, Railkar RA, Musser BJ, Cote J, Ederveen A, Krefetz DG, DeNoia E, Free AL, Morrow L, Chakravarthy MV, Kauh E, Tatosian DA, Kothare PA. Krug AW, et al. Among authors: morrow l. Clin Transl Sci. 2017 Sep;10(5):404-411. doi: 10.1111/cts.12479. Epub 2017 Jul 20. Clin Transl Sci. 2017. PMID: 28727908 Free PMC article. Clinical Trial.
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, Meyers C, Buchsbaum MS, Neelakantham S, Swan T, Filosa LA, Laurent D, Petricoul O, Zakaria M. Garito T, et al. Among authors: morrow l. Diabetes Obes Metab. 2018 Jan;20(1):94-102. doi: 10.1111/dom.13042. Epub 2017 Aug 2. Diabetes Obes Metab. 2018. PMID: 28643356 Clinical Trial.
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.
Beysen C, Schroeder P, Wu E, Brevard J, Ribadeneira M, Lu W, Dole K, O'Reilly T, Morrow L, Hompesch M, Hellerstein MK, Li K, Johansson L, Kelly PF. Beysen C, et al. Among authors: morrow l. Diabetes Obes Metab. 2021 Mar;23(3):700-710. doi: 10.1111/dom.14272. Epub 2020 Dec 21. Diabetes Obes Metab. 2021. PMID: 33289350 Free PMC article. Clinical Trial.
389 results